890 results on '"Futreal, Andrew"'
Search Results
2. Author Correction: Longitudinal single-cell profiling reveals molecular heterogeneity and tumor-immune evolution in refractory mantle cell lymphoma
3. Multiregional transcriptomic profiling provides improved prognostic insight in localized non-small cell lung cancer
4. METI: deep profiling of tumor ecosystems by integrating cell morphology and spatial transcriptomics
5. Intratumoral microbiome of adenoid cystic carcinomas and comparison with other head and neck cancers
6. Author Correction: Distinct molecular and immune hallmarks of inflammatory arthritis induced by immune checkpoint inhibitors for cancer therapy
7. Comprehensive characterization of IFNγ signaling in acute myeloid leukemia reveals prognostic and therapeutic strategies
8. A randomized, non-comparative phase 2 study of neoadjuvant immune-checkpoint blockade in retroperitoneal dedifferentiated liposarcoma and extremity/truncal undifferentiated pleomorphic sarcoma
9. The “Great Debate” at Immunotherapy Bridge 2021, December 1st–2nd, 2021
10. DCIS knowledge of women choosing between active surveillance and surgery for low-risk DCIS
11. Atlas of Metastatic Gastric Cancer Links Ferroptosis to Disease Progression and Immunotherapy Response
12. Interferon signaling promotes tolerance to chromosomal instability during metastatic evolution in renal cancer
13. Pan-cancer T cell atlas links a cellular stress response state to immunotherapy resistance
14. Exploratory analysis of the cervix tumoral HPV antigen-specific T-cell repertoire during chemoradiation and after brachytherapy
15. PBRM1-deficient PBAF complexes target aberrant genomic loci to activate the NF-κB pathway in clear cell renal cell carcinoma
16. Tumor-resident Lactobacillus iners confer chemoradiation resistance through lactate-induced metabolic rewiring
17. Archival single-cell genomics reveals persistent subclones during DCIS progression
18. Evolution of immune and stromal cell states and ecotypes during gastric adenocarcinoma progression
19. Proteogenomic landscape of gastric adenocarcinoma peritoneal metastases
20. Single cell clonotypic and transcriptional evolution of multiple myeloma precursor disease
21. Clinical Characteristics and Cause of Death Among Hospitalized Decedents With Cancer and COVID-19
22. Comprehensive multiplexed immune profiling of the ductal carcinoma in situ immune microenvironment regarding subsequent ipsilateral invasive breast cancer risk
23. Young-onset Rectal Cancer: Unique Tumoral Microbiome and Correlation with Response to Neoadjuvant Therapy
24. Probabilistic graph-based model uncovers previously unseen druggable vulnerabilities in major solid cancers
25. Durvalumab plus tremelimumab in advanced or metastatic soft tissue and bone sarcomas: a single-centre phase 2 trial
26. TIGIT is the central player in T-cell suppression associated with CAR T-cell relapse in mantle cell lymphoma
27. Metagenomes of rectal swabs in larger, advanced stage cervical cancers have enhanced mucus degrading functionalities and distinct taxonomic structure
28. Lineage-coupled clonal capture identifies clonal evolution mechanisms and vulnerabilities of BRAFV600E inhibition resistance in melanoma
29. Distinct molecular and immune hallmarks of inflammatory arthritis induced by immune checkpoint inhibitors for cancer therapy
30. Mechanisms that clear mutations drive field cancerization in mammary tissue.
31. Patient–reported fatigue prior to treatment is prognostic of survival in patients with acute myeloid leukemia
32. Sequencing of prostate cancers identifies new cancer genes, routes of progression and drug targets
33. Supplemental Figure 1 from Efficacy and Safety of Atezolizumab and Bevacizumab in Appendiceal Adenocarcinoma
34. Data from Efficacy and Safety of Atezolizumab and Bevacizumab in Appendiceal Adenocarcinoma
35. Supplementary Tables from Efficacy and Safety of Atezolizumab and Bevacizumab in Appendiceal Adenocarcinoma
36. TABLE 1 from Efficacy and Safety of Atezolizumab and Bevacizumab in Appendiceal Adenocarcinoma
37. Supplemental Figure 2 from Efficacy and Safety of Atezolizumab and Bevacizumab in Appendiceal Adenocarcinoma
38. Supplementary Table S6 from Integrative Molecular Analyses of the MD Anderson Prostate Cancer Patient-derived Xenograft (MDA PCa PDX) Series
39. Data from Integrative Molecular Analyses of the MD Anderson Prostate Cancer Patient-derived Xenograft (MDA PCa PDX) Series
40. Supplementary Figure S4 from Integrative Molecular Analyses of the MD Anderson Prostate Cancer Patient-derived Xenograft (MDA PCa PDX) Series
41. The evolution of lung adenocarcinoma precursors is associated with chromosomal instability and transition from innate to adaptive immune response/evasion
42. Case report: Molecular profiling facilitates the diagnosis of a challenging case of lung cancer with choriocarcinoma features
43. Integrative Molecular Analyses of the MD Anderson Prostate Cancer Patient-derived Xenograft (MDA PCa PDX) Series
44. Clonal dominance defines metastatic dissemination in pancreatic cancer
45. Future cancer research priorities in the USA: a Lancet Oncology Commission
46. Activating NOTCH1 Mutations Define a Distinct Subgroup of Patients With Adenoid Cystic Carcinoma Who Have Poor Prognosis, Propensity to Bone and Liver Metastasis, and Potential Responsiveness to Notch1 Inhibitors
47. Genetic determinants of immune-related adverse events in patients with melanoma receiving immune checkpoint inhibitors
48. Mechanisms that clear mutations drive field cancerization in mammary tissue
49. Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial
50. Ductal carcinoma in situ develops within clonal fields of mutant cells in morphologically normal ducts.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.